Загрузка...
Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer
First-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib and erlotinib, have proven to be highly effective agents for advanced non-small cell lung cancer (NSCLC) in patients harboring an activating EGFR mutation such as the exon 19 deletion mutati...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Baishideng Publishing Group Inc
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4129529/ https://ncbi.nlm.nih.gov/pubmed/25302168 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5306/wjco.v5.i4.646 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|